尽管面临财政损失和竞争,但基因治疗领导者CRISPR的治疗疗法却扩大了试验范围。 CRISPR Therapeutics, a gene therapy leader, expands trials despite facing financial losses and competition.

CRISPR 治疗疗法以经林业发展局批准的用于治疗镰状细胞疾病的Casgevy基因疗法而著称,它有19亿美元的现金,并正在扩大肿瘤学、心脏病学和糖尿病方面的临床试验。 CRISPR Therapeutics, known for its FDA-approved gene therapy Casgevy for sickle cell disease, has $1.9 billion in cash and is expanding its clinical trials in oncology, cardiology, and diabetes. 尽管Casgevy成本高,为220万美元,但该公司预计到2025年将获得1.32亿美元的收入。 Despite the high cost of Casgevy at $2.2 million, the company projects $132 million in revenue by 2025. 但是,它面临着财政损失和其他生物技术公司的竞争,促使投资者谨慎行事。 However, it faces financial losses and competition from other biotech firms, prompting investors to exercise caution.